Literature DB >> 18561992

Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer.

Chad A Hamilton1, G Larry Maxwell, Mildred R Chernofsky, Sarah A Bernstein, John H Farley, G Scott Rose.   

Abstract

BACKGROUND: Malignant ascites often has a profound impact on the quality of life of patients with refractory ovarian cancer. Current treatments, including dietary, medical, and procedural are often temporary and unsatisfactory options in patients approaching the end of life. CASE: We present a case of an 88 year-old receiving home hospice care with refractory ovarian cancer and severe symptomatic ascites. We performed a paracentesis and treated her with intraperitoneal bevacizumab with dramatic improvement in her ascites and the quality of her final weeks of life.
CONCLUSION: Intraperitoneal bevacizumab may be a useful tool in the palliation of malignant ascites and is worthy of further study.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18561992     DOI: 10.1016/j.ygyno.2008.04.028

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  26 in total

Review 1.  Health-related quality of life in ovarian cancer patients and its impact on clinical management.

Authors:  Dana M Chase; Lari Wenzel
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2011-08       Impact factor: 2.217

2.  A pilot study of combination intraperitoneal recombinant human endostatin and chemotherapy for refractory malignant ascites secondary to ovarian cancer.

Authors:  Jing Zhao; Xinxiao Chen; Aimu Zhang; Feng Xu; Meilong Hu; Congying Xie; Shengliu Xue
Journal:  Med Oncol       Date:  2014-03-22       Impact factor: 3.064

3.  Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer.

Authors:  Daniel T Rein; Anne Kathrin Volkmer; Jens Volkmer; Ines M Beyer; Wolfgang Janni; Markus C Fleisch; Anne Kathrin Welter; Dirk Bauerschlag; Thomas Schöndorf; Martina Breidenbach
Journal:  Oncol Lett       Date:  2012-01-03       Impact factor: 2.967

4.  Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial.

Authors:  Hui Zhao; Xiaosong Li; Dianjun Chen; Jianhua Cai; Yan Fu; Huanrong Kang; Jie Gao; Ke Gao; Nan Du
Journal:  Med Oncol       Date:  2015-01-22       Impact factor: 3.064

Review 5.  Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.

Authors:  Emma Kipps; David S P Tan; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2013-02-21       Impact factor: 60.716

6.  The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.

Authors:  Markus M Heiss; Pawel Murawa; Piotr Koralewski; Elzbieta Kutarska; Olena O Kolesnik; Vladimir V Ivanchenko; Alexander S Dudnichenko; Birute Aleknaviciene; Arturas Razbadauskas; Martin Gore; Elena Ganea-Motan; Tudor Ciuleanu; Pauline Wimberger; Alexander Schmittel; Barbara Schmalfeldt; Alexander Burges; Carsten Bokemeyer; Horst Lindhofer; Angelika Lahr; Simon L Parsons
Journal:  Int J Cancer       Date:  2010-11-01       Impact factor: 7.396

Review 7.  Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review.

Authors:  Filippo Bellati; Chiara Napoletano; Ilary Ruscito; Maria Pastore; Milena Pernice; Morena Antonilli; Marianna Nuti; Pierluigi Benedetti Panici
Journal:  Invest New Drugs       Date:  2009-11-24       Impact factor: 3.850

Review 8.  The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.

Authors:  Michael Bradshaw; Aaron Mansfield; Tobias Peikert
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

9.  Intraperitoneal bevacizumab combined with cytoreductive surgery: a pre-clinical study of tolerance and pharmacokinetics in an animal model.

Authors:  Guillaume Passot; Aurélien Dupré; Michel Rivoire; Faheez Mohamed; Naoual Bakrin; Olivier Glehen
Journal:  Clin Transl Oncol       Date:  2012-07-24       Impact factor: 3.405

10.  Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab.

Authors:  Aflah Roohullah; Hui-Li Wong; Katrin M Sjoquist; Peter Gibbs; Kathryn Field; Ben Tran; Jeremy Shapiro; Joe Mckendrick; Desmond Yip; Louise Nott; Val Gebski; Weng Ng; Wei Chua; Timothy Price; Niall Tebbutt; Lorraine Chantrill
Journal:  World J Gastroenterol       Date:  2015-05-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.